Transcutaneous delivery of tetanus toxin Hc fragment induces superior tetanus toxin neutralizing antibody response compared to tetanus toxoid

Human Vaccines

Volumn 5, Issue 4, 2009, Pages 230-236

  Johnston, Louise ^a   Mawas, Fatme ^a   Tierney, Rob ^a   Qazi, Omar ^b   Fairweather, Neil ^b   Sesardic, Dorothea ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Tetanus; Toxin Hc mutants; Toxoid toxin Hc fragments; Transcutaneous delivery

Indexed keywords

IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; TETANUS TOXIN; TETANUS TOXOID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BINDING AFFINITY; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; MOUSE; NONHUMAN; TARGET CELL; VACCINATION;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTITOXINS; FEMALE; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; PEPTIDE FRAGMENTS; TETANUS TOXIN; TETANUS TOXOID;

EID: 68049090953     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.5.4.6877     Document Type: Article

References (51)

1. Farrar JJ, Yen LM, Cook T, Fairweather N, Binh N, Parry J, et al. Tetanus. J Neurol Neurosurg Psychiatry 2000; 69:292-301.
2. Montecucco C, Schiavo G. Tetanus and botulism neurotoxins: a new group of zinc proteases. Trends Biochem Sci 1993; 18:324-7.
3. Schiavo G, Benfenati F, Poulain B, Rossetto O, Polverino de LP, DasGupta BR, et al. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992; 359:832-5.
4. Lalli G, Herreros J, Osborne SL, Montecucco C, Rossetto O, Schiavo G. Functional characterization of tetanus and botulinum neurotoxins binding domains. J Cell Sci 1999; 112:2715-24.
5. Sinha K, Box M, Lalli G, Schiavo G, Schneider H, Groves M, et al. Analysis of mutants of tetanus toxin Hc fragment: ganglioside binding, cell binding and retrograde axonal transport properties. Mol Microbiol 2000; 37:1041-51.
6. Robbins JB, Schneerson R, Trollfors B, Sato H, Sato Y, Rappuoli R, et al. The diphtheria and pertussis components of diphtheria-tetanus toxoid-pertussis vaccine should be genetically inactivated mutant toxins. J Infect Dis 2005; 191:81-8.
7. Moghaddam A, Olszewska W, Wang B, Tregoning JS, Helson R, Sattentau QJ, et al. A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat Med 2006; 12:905-7.
8. Helting TB, Nau HH. Analysis of the immune response to papain digestion products of tetanus toxin. Acta Pathol Microbiol Immunol Scand [C] 1984; 92:59-63.
9. Makoff AJ, Oxer MD, Romanos MA, Fairweather N, Ballantine S. Expression of tetanus toxin fragment C in E. coli: high level expression by removing rare codons. Nucleic Acids Res 1989; 17:10191-202.
10. Qazi O, Sesardic D, Tierney R, Söderback Z, Crane D, Bolgiano B, et al. Reduction of the ganglioside binding activity of the tetanus toxin Hc fragment destroys immunogenicity: implications for development of novel tetanus vaccines. Infect Immun 2006; 74:4884-91.
11. Fairweather N, Chatfield S, Makoff AJ, Strugnell RA, Bester J, Maskell DJ, et al. Oral vaccination of mice against tetanus by use of a live, attenuated Salmonella carrier. Infect Immun 1990; 58:1323-6.
12. Tacket CO, Galen J, Sztein MB, Losonsky G, Wyant TL, Nataro J, et al. Safety and immune responses to attenuated Salmonella enterica serovar typhi oral live vector vaccines expressing tetanus toxin fragment C. Clin Immunol 2000; 97:146-53.
13. Tregoning JS, Clare S, Bowe F, Edwards L, Fairweather N, Qazi O, et al. Protection against tetanus toxin using a plant-based vaccine. Eur J Immunol 2005; 35:1320-6.
14. Tregoning JS, Nixon P, Kuroda H, Svab B, Clare S, Bowe F, et al. Expression of tetanus toxin Fragment C in tobacco chloroplasts. Nucleic Acids Res 2003; 31:1174-9.
15. Anderson R, Gao XM, Papakonstantinopoulou A, Roberts M, Dougan G. Immune response in mice following immunization with DNA encoding fragment C of tetanus toxin. Infect Immun 1996; 64:3168-73.
16. Dietz V, Milstien JB, van Cochi LFS, Bennett J. Performance and potency of tetanus toxoid: implications for eliminating neonatal tetanus. Bull World Health Organ 1996; 74:619-28.
17. Vandelaer J, Birmingham M, Gasse F, Kurian M, Shaw C, Garnier S. Tetanus in developing countries: an update on the Maternal and Neonatal Tetanus Elimination Initiative. Vaccine 2003; 21:3442-5.
18. Simonsen L, Kane A, Lloyd J, Zaffran M, Kane M. Unsafe injections in the developing world and transmission of blood-borne pathogens: a review. Bull World Health Organ 1999; 77:789-800.
19. Hammond SA, Guebre-Xabier M, Yu J, Glenn GM. Transcutaneous immunization: an emerging route of immunization and potent immunostimulation strategy. Crit Rev Ther Drug Carrier Syst 2001; 18:503-26.
20. Partidos CD, Beignon AS, Mawas F, Belliard G, Briand JP, Muller S. Immunity under the skin: potential application for topical delivery of vaccines. Vaccine 2003; 21:776-80.
21. Kane A, Lloyd J, Zaffran M, Simonsen L, Kane M. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. Bull World Health Organ 1999; 77:801-7.
22. Glenn GM, Scharton-Kersten T, Vassell R, Matyas GR, Alving CR. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. Infect Immun 1999; 67:1100-6.
23. Glenn GM, Villar C, Flyer DC, Bourgeois AL, McKenzie R, Lavker RM, et al. Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: Use of skin pre-treatment to disrupt the stratum corneum. Infect Immun 2007; 75:2163-70.
24. Scharton-Kersten T, Yu J, Vassell R, O'Hagan D, Alving CR, Glenn GM. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits and unrelated adjuvants. Infect Immun 2000; 68:5306-13.
25. Ghose C, Kalsy A, Shiekh A, Rollenhagen J, John M, Young J, et al. Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A neutralizing antibodies in mice. Infect Immun 2007; 75:2826-32.
26. Tierney R, Beignon AS, Rappuoli R, Muller S, Sesardic D, Partidos CD. Transcutaneous immunization with tetanus toxoid and mutants of Escherichia coli heat-labile enterotoxin as adjuvants elicits strong protective antibody responses. J Infect Dis 2003; 188:753-8.
27. Glenn GM, Rao M, Matyas GR, Alving CR. Skin immunization made possible by cholera toxin. Nature 1998; 391:851.
28. Beignon AS, Briand JP, Muller S, Partidos CD. Immunization onto bare skin with heat-labile enterotoxin of Escherichia coli enhances immune responses to co-administered protein and peptide antigens and protects mice against lethal toxin challenge. Immunology 2001; 102:344-51.
29. Mawas F, Peyre M, Beignon AS, Frost L, Del GG, Rappuoli R, et al. Successful induction of protective antibody responses against Haemophilus influenzae type b and diphtheria after transcutaneous immunization with the glycoconjugate polyribosyl ribitol phosphate-cross-reacting material 197 vaccine. J Infect Dis 2004; 190:1177-82.
30. Babiuk S, Baca-Estrada ME, Pontarollo R, Foldvari M. Topical delivery of plasmid DNA using biphasic lipid vesicles (Biphasix). J Pharm Pharmacol 2002; 54:1609-14.
31. Foldvari M, Babiuk S, Badea I. DNA delivery for vaccination and therapeutics through the skin. Curr Drug Deliv 2006; 3:17-28.
32. Peachman KK, Rao M, Alving CR. Immunization with DNA through the skin. Methods 2003; 31:232-42.
33. Glenn GM, Taylor DN, Li X, Frankel S, Montemarano A, Alving CR. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat Med 2000; 6:1403-6.
34. Etchart N, Hennino A, Friede M, Dahel K, Dupouy M, Goujon-Henry C, et al. Safety and efficacy of transcutaneous vaccination using a patch with the live-attenuated measles vaccine in humans. Vaccine 2007; 25:6891-9.
35. Guerena-Burgueno F, Hall ER, Taylor DN, Cassels FJ, Scott DA, Wolf MK, et al. Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect Immun 2002; 70:1874-80.
36. McKenzie R, Bourgeois AL, Frech SA, Flyer DC, Bloom A, Kazempour K, et al. Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): Protective efficacy in a double-blind, placebo-controlled challenge study. Vaccine 2007; 25:3684-91.
37. Glenn GM, Flyer DC, Ellingsworth LR, Frech SA, Frerichs DM, Seid RC Jr, et al. Transcutaneous immunization with heat-labile enterotoxin: Development of a needle-free vaccine patch. Expert Rev Vaccines 2007; 6:809-19.
38. Naito S, Maeyama J, Mizukami T, Takahashi M, Hamaguchi I, Yamaguchi K. Transcutaneous immunization by merely prolonging the duration of antigen presence on the skin of mice induces a potent antigen-specific antibody response even in the absence of an adjuvant. Vaccine 2007; 25:8762-70.
39. Uddowla S, Freytag LC, Clements JD. Effect of adjuvants and route of immunization on the immune response to recombinant plague antigens. Vaccine 2007; 25:477984-93.
40. 197 boosts functional antibody levels in mice primed parenterally with adsorbed diphtheria toxoid vaccine. Infect Immun 2008; 76:1766-73.
41. Belyakov I, Hammond MSA, Ahlers JD, Glenn GM, Berzofsky JA. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J Clin Invest 2004; 113:998-1007.
42. Rechtsteiner G, Warger T, Osterloh P, Schild H, Radsak MP. Cutting edge: Priming of CTL by transcutaneous peptide immunization with imiquimod. J Immunol 2005; 174:2476-80.
43. 197, of Diphtheria toxin. Infect Immun 2005; 73:4803-9.
44. Tezel A, Paliwal S, Shen Z, Mitragotri S. Low-frequency ultrasound as a transcutaneous immunization. Vaccine 2005; 23:3800-7.
45. Upadhyay P. Enhanced transdermal-immunization with diphtheria toxoid using local hyperthermia. Vaccine 2006; 24:5593-8.
46. Dell K, Koesters R, Gissmann L. Transcutaneous immunization in mice: induction of T-helper and cytotoxic T lymphocyte responses and protection against human papillomavirus-induced tumors. Int J Cancer 2006; 118:364-72.
47. Vogt A, Mahe B, Costagliola D, Bonduelle O, Hadam S, Schaefer G, et al. Transcutaneous anti-influenza vaccination promotes both CD4 and CD8 T cell immune responses in humans. J Immunology 2008; 180:1482-9.
48. McNeela E, Jabbal-Gill AI, Illum EAL, Rappuoli R, Padda A, Lewis DJ, et al. Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan. Vaccine 2004; 22:909-14.
49. Little SF, Ivins BE, Webster WM, Norris SLW, Andrews GP. Effect of aluminum hydroxide adjuvant and formaldehyde in the formulation of rPA anthrax vaccine. Vaccine 2007; 25:2771-7.
50. Nencioni L, Volpini G, Peppoloni S, Bugnoli M, De Magistris MT, Marsili I, et al Properties of pertussis toxin mutant PT-9K/129G after formaldehyde treatment. Infect Immun 1991; 59:625-30.
51. Test for bacterial endotoxin. European Pharmacopoeia. 2008; 20614.